+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Global Spinal Muscular Atrophy Treatment Market 2019-2023 - Product Image

Global Spinal Muscular Atrophy Treatment Market 2019-2023

  • ID: 4668766
  • Report
  • Region: Global
  • 99 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

About this market

With the increase in development of new innovative therapies, there is a growing demand for spinal muscular atrophy treatment. The market is witnessing an increase in the development of new innovative therapies for the treatment of spinal muscular atrophy. For instance, two innovative new therapies for type 1 spinal muscular atrophy have proven to be highly effective in ongoing clinical trials. The first therapy employed a DNA-loaded virus to replace the missing SMN1 gene with a fresh copy of the gene. The second therapy, which has already been approved by the FDA, is called nusinersen (SPINRAZA). It promotes the production of the nerve protein by SMN2. These two therapies have improved the motor function in babies. AveXis in 2018, entered into a licensing agreement with Genethon for the in vivo gene therapy delivery of AAV9 vector into the CNS for the treatment of spinal muscular atrophy. The analysts have predicted that the spinal muscular atrophy treatment market will register a CAGR of almost 23% by 2023.

Market Overview

Rising number of initiatives being taken by organizations to provide patient care
Several organizations are taking initiatives to provide the best care to patients suffering from spinal muscular atrophy, and some organizations such as Cure SMA are offering care packages and family support staff to newly diagnosed patients.

Low adoption of spinal muscular atrophy treatment
One of the major challenges faced in the market is low adoption of spinal muscular atrophy drug therapy as patients have a higher propensity towards other approaches, such as physiotherapy, nutritional support, respiratory care, and enablement strategies.

For the detailed list of factors that will drive and challenge the growth of the spinal muscular atrophy treatment market during the 2019-2023 period, view the full report.

Competitive Landscape
The market appears to be highly concentrated and with the presence of Biogen, the market is expected to grow less concentrated with the emergence of new players during the forecast period. Factors such as increase in development of new innovative therapies and rising number of initiatives being taken by organizations to provide patient care, will provide considerable growth opportunities to spinal muscular atrophy treatment companies. Biogen is the major company covered in this report.
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: PIPELINE ANALYSIS
  • Pipeline analysis
  • PART 05: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 06: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 07: MARKET SEGMENTATION BY TYPE
  • Market segmentation by type
  • Comparison by type
  • Type 2 - Market size and forecast 2018-2023
  • Type 3 - Market size and forecast 2018-2023
  • Type 1 - Market size and forecast 2018-2023
  • Type 4 - Market size and forecast 2018-2023
  • Market opportunity by type
PART 08: CUSTOMER LANDSCAPE

PART 09: MARKET SEGMENTATION BY TREATMENT
  • Segmentation by treatment
PART 10: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • Americas - Market size and forecast 2018-2023
  • EMEA - Market size and forecast 2018-2023
  • APAC - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 11: DECISION FRAMEWORK

PART 12: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 13: MARKET TRENDS
  • Rising awareness of treatment and diagnosis of spinal muscular atrophy
  • Development of new innovative therapies for treatment
  • Advances in diagnostic techniques
PART 14: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
PART 15: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Biogen
PART 16: APPENDIX
  • Research methodology
  • List of abbreviations
PART 17: About the Author


List of Exhibits
Exhibit 01: Global CNS disorder drugs market
Exhibit 02: Segments of global cns disorder drugs market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Late-stage pipeline agents for spinal muscular atrophy
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Type - Market share 2018-2023 (%)
Exhibit 19: Comparison by type
Exhibit 20: Type 2 - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Type 2 - Year-over-year growth 2019-2023 (%)
Exhibit 22: Type 3 - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Type 3 - Year-over-year growth 2019-2023 (%)
Exhibit 24: Type 1 - Market size and forecast 2018-2023 ($ millions)
Exhibit 25: Type 1 - Year-over-year growth 2019-2023 (%)
Exhibit 26: Type 4 - Market size and forecast 2018-2023 ($ millions)
Exhibit 27: Type 4 - Year-over-year growth 2019-2023 (%)
Exhibit 28: Market opportunity by type
Exhibit 29: Customer landscape
Exhibit 30: Market share by geography 2018-2023 (%)
Exhibit 31: Geographic comparison
Exhibit 32: Americas - Market size and forecast 2018-2023 ($ millions)
Exhibit 33: Americas - Year-over-year growth 2019-2023 (%)
Exhibit 34: EMEA - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: EMEA - Year-over-year growth 2019-2023 (%)
Exhibit 36: APAC - Market size and forecast 2018-2023 ($ millions)
Exhibit 37: APAC - Year-over-year growth 2019-2023 (%)
Exhibit 38: Key leading countries
Exhibit 39: Market opportunity
Exhibit 40: Impact of drivers and challenges
Exhibit 41: Vendor landscape
Exhibit 42: Landscape disruption
Exhibit 43: Vendors covered
Exhibit 44: Vendor classification
Exhibit 45: Market positioning of vendors
Exhibit 46: Biogen - Vendor overview
Exhibit 47: Biogen - Business segments
Exhibit 48: Biogen - Organizational developments
Exhibit 49: Biogen - Geographic focus
Exhibit 50: Biogen - Key offerings
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

Global Spinal Muscular Atrophy Treatment Market 2019-2023

The author of the report recognizes the following company as the key player in the global spinal muscular atrophy treatment market: Biogen.

Commenting on the report, an analyst from the research team said: “One trend affecting this market is the development of new innovative therapies for treatment. The market is witnessing an increase in the development of new innovative therapies for the treatment of spinal muscular atrophy. For instance, two innovative new therapies for type 1 spinal muscular atrophy have proven to be highly effective in ongoing clinical trials.”

According to the report, one driver influencing this market is the driven by the rising number of initiatives being taken by organizations to provide patient care. Several organizations are taking initiatives to provide the best care to patients suffering from spinal muscular atrophy, and some organizations such as Cure SMA are offering care packages and family support staff to newly diagnosed patients.

Further, the report states that one challenge affecting this market is the low adoption of spinal muscular atrophy treatment. One of the major challenges faced in the market is low adoption of spinal muscular atrophy drug therapy as patients have a higher propensity towards other approaches, such as physiotherapy, nutritional support, respiratory care, and enablement strategies.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • Biogen
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4668766
Adroll
adroll